Skip to main content

User menu

  • Sign in
  • Register

Main menu

  • Pfizer Medicines
  • Therapy Areas
  • News
  • Materials
  • Useful Links

Search form

Pfizer Home

Useful Resources

  • Video Resources (18)
  • Materials and Tools (20)
  • For your patients (1)
  • Links and resources (1)
  • Support and services (6)
  • A Diagnostic Driven Approach to IFIs
  • Categories of Anticoagulants
  • Cresemba® Mode of Action
  • Dosing Guide
  • Downloadable resources for healthcare professionals
  • Educational Videos: Zavicefta in Clinical Practice
  • Educational videos: MDR Gram negative infections
  • Fragmin® Patient Resources
  • Fragmin® Presentations
  • Fragmin® Tolerability
  • GroAssist® - patient support app
  • Guidelines
  • How XELJANZ Works
  • Inflammatory Bowel Disease
  • Mechanism of Action
  • Optimising Treatment with Inflectra®
  • Order materials
  • Paediatric Studies
  • Patient Resources
  • Prescribing Information
  • Safety and Tolerability
  • Sayana® Press Patient website
  • Useful Resources Homepage
  • Using Fragmin® Needle-Trap
  • XELJANZ Events
  • Zinforo Video Resources

This site is intended only for healthcare professionals resident in the United Kingdom

Video Resources

On Demand

Dr Erling Donnelly

Pfizer Oncology

Dr Erling Donnelly, Head of Oncology, Pfizer UK on Pfizer's commitment to the oncology community through the COVID-19 pandemic.

  • Prescribing Information
IDD Video Thumbnail
On Demand

Dispense and Delivery Service

Pfizer Oncology

Ibrance Dispense and Delivery Service provides home delivery to registered patients.

How can Pfizer's Ibrance Dispense and Delivery Service help your hospital trust to deliver care closer to home? Watch the video below to find out more.

  • Patients must be receiving Ibrance in accordance with the marketing authorisation
  • HCPs maintain responsibility for blood monitoring, dose modification and prescription generation

This service is funded by Pfizer Ltd, the manufacturer of Ibrance and is provided by Alcura on behalf of Pfizer Ltd.

  • Prescribing Information
On Demand

XELJANZ in Rheumatoid Arthritis

Dr Gary Meenagh

In this video, Dr Gary Meenagh discusses his experience prescribing XELJANZ in RA.
 

  • Prescribing Information
On Demand

XELJANZ in Rheumatoid Arthritis

Dr David Hutchinson

In this video, Dr David Hutchinson discusses his experience prescribing XELJANZ in RA.

 

  • Prescribing Information
On Demand

XELJANZ in Psoriatic Arthritis

Dr Richard Smith

In this video, Dr Richard Smith discusses his experience prescribing XELJANZ in PsA.

 

  • Prescribing Information
On Demand

IBRANCE: Breast cancer simulation

Pfizer Oncology

The Ibrance Simulator is a Promotion resource, used by Pfizer Oncology Healthcare Development Managers, that will be used in Ibrance Promotional conversations.

Discrete event simulation is an effective form of scenario generation and engagement around service transformation for healthcare. It can be used to model hospital departments, pathways or entire health economies in an animated and compelling manner.

Simulations are communication tools. They open debate, they enable conversations and engender close working with hospitals and wider healthcare commissioning towards all round healthcare improvements.

The objective of the Ibrance simulation model is to demonstrate, to NHS stakeholders, the benefits of adopting Ibrance for the treatment of ER +ve, HER2 -ve patients with advanced breast cancer in the following key points:

  1. Firstly the freeing of capacity in the chemotherapy clinic and cost savings by adopting Ibrance to delay disease progression and chemotherapy treatment.
  2. Secondly, further Service optimisation by moving away from a consultant led or secondary care led service where appropriate.

The results from all scenarios can be exported into a results summary and, on request, the Results Summary Document and Data Analytics resource, can be provided to Healthcare Professions (HCPs) directly from the resource.

How could IBRANCE make a difference to your service capacity and Optimisation ?

  • Prescribing Information
On Demand

If not you, then who?

Dr. Roger Henderson - Senior GP, Shropshire

Ever wondered how you can discuss smoking cessation in a COPD consultation? Or what does a brief consultation on smoking cessation look like?  These webinars bring solutions to these two challenges, to life.

  • Prescribing Information
On Demand

PALOMA-2 trial

Pfizer

This 3 minute animation video which provides an overview of the PALOMA-2 trial consisting of information such as study design, efficacy and quality of life (QoL). Once you have viewed the video and if you require further information please select the relevant tabs.

  • Prescribing Information
On Demand

Implementing smoking cessation in hospitals

Matthew Evison - Consultant in Respiratory Medicine, Greater Manchester

Gareth Jones - Consultant Respiratory Physician, Royal Liverpool University Hospital

Hosted by Noel Baxter, GP and clinical commissioner for NHS Southwark and chair elect for the Primary Care Respiratory Society UK (PCRS-UK).

  • Prescribing Information
On Demand

Best practices for ROS1 testing in NSCLC patients

Professor Andrew Nicholson

Should we be reflex-ROS1 testing on ALL lung cancer patients? Professor Nicholson gives his professional opinion on this question and others including tips for laboratories who want to validate their own ROS1 testing service.

  • Prescribing Information
  • 1
  • 2
  • next ›
  • last »
Pfizer Home

Useful Resources

  • Video Resources (18)
  • Materials and Tools (20)
  • For your patients (1)
  • Links and resources (1)
  • Support and services (6)
  • A Diagnostic Driven Approach to IFIs
  • Categories of Anticoagulants
  • Cresemba® Mode of Action
  • Dosing Guide
  • Downloadable resources for healthcare professionals
  • Educational Videos: Zavicefta in Clinical Practice
  • Educational videos: MDR Gram negative infections
  • Fragmin® Patient Resources
  • Fragmin® Presentations
  • Fragmin® Tolerability
  • GroAssist® - patient support app
  • Guidelines
  • How XELJANZ Works
  • Inflammatory Bowel Disease
  • Mechanism of Action
  • Optimising Treatment with Inflectra®
  • Order materials
  • Paediatric Studies
  • Patient Resources
  • Prescribing Information
  • Safety and Tolerability
  • Sayana® Press Patient website
  • Useful Resources Homepage
  • Using Fragmin® Needle-Trap
  • XELJANZ Events
  • Zinforo Video Resources

Janrain Capture

  • Register / Sign in

Footer menu

  • Report Adverse Events
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • Pfizer.co.uk

Copyright footer block

Copyright © 2016-2020 Pfizer Limited. All rights reserved.
This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ, VAT registration number GB201048427.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit
www.medicines.org.uk/emc.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
PP-PFE-GBR-2464. April 2020

For healthcare professionals only*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select ‘No’, you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer’s prescription medicines.

*The ABPI Code definition of healthcare professional is members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-GIP-GBR-3015 March 2018

YesNo
Your login attempt failed. Please try again.

{* message_withExistingAccount *}

{* loginWidget *}

{* message_joinNow *}

{* message_joinNowText *}

{* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}
{* traditionalSignIn_signInButton *}

{* message_forgotPassword *}
{* /userInformationForm *}
{* traditionalSignIn_createButton *}

{* message_signIn *}

Your login attempt failed. Please try again.

{* message_welcomeBack *}

{* loginWidget *}
{* message_useAnotherAccount *}
Your login attempt failed. Please try again.

{* message_welcomeBack *}

{* #userInformationForm *} {* traditionalSignIn_emailAddress *} {* traditionalSignIn_password *}
{* traditionalSignIn_signInButton *}

{* message_forgotPassword *}
{* /userInformationForm *}
{* message_useAnotherAccount *}

{* message_registeringThankYou *}

{* message_confirmEmailSent *}

{* message_close *}

{* message_confirmTraditionalInformation *} {* message_alreadyHaveAccount *}

* Required Information

{* #registrationForm *} {* salutation *} {* givenName *} {* familyName *} {* email *}
{* designation_name *} {* designation_specialty *} {* designation_specialty2 *} {* designation_specialty_json *} {* primaryAddress_workplace *} {* primaryAddress_postalCode *} {* phoneNumber_work *} {* license_number *} {* traditionalRegistration_password *} {* traditionalRegistration_passwordConfirm *} {* acknowledgement_professional *} {* acknowledgement_consent *} {* acknowledgement_terms *}
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."
{* hidden_programType *} {* hidden_campaign *} {* hidden_siteId *} {* hidden_preferredLanguage *} {* hidden_residencyCountry *}

PP-PFE-GBR-2768 September 2020
{* backButton *}
{* createAccountButton *}
{* /registrationForm *}
{*#postLoginAcceptanceForm*}

{* message_legalText *}

{* postLoginAcceptanceButton *}
{*/postLoginAcceptanceForm*}

{* message_emailPasswordResetInstructions *}

{* #forgotPasswordForm *} {* traditionalSignIn_emailAddress *}
{* backButton *}
{* forgotPassword_sendButton *}
{* /forgotPasswordForm *}

{* message_emailPasswordResetSent *}

{* message_close *}
{* mergeAccounts *}
{* #tradAuthenticateMergeForm *} {* traditionalSignIn_emailAddress *} {* mergePassword *}
{* backButton *}
{* traditionalSignIn_signInButton *}
{* /tradAuthenticateMergeForm *}